Hospital of Southern Norway Trust
10
5
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
20%
2 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Role: collaborator
Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)
Role: collaborator
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors
Role: collaborator
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
Role: collaborator
Advanced Care Planning for the Severely Ill Home-dwelling Elderly
Role: collaborator
Guided Internet-Based Treatment for Harmful Alcohol Use; EBehandling Alkohol
Role: collaborator
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Role: collaborator
Improved Therapy Response Assessment in Metastatic Brain Tumors
Role: collaborator
Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery
Role: collaborator
Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS
Role: lead
All 10 trials loaded